Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | FAAH | O00519 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALOX12 | P18054 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.98 |
| ▸ | HRH1 | P35367 | 7/20 | 0.67 |
| ▸ | HTR2A | P28223 | 6/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.67 |
| ▸ | DRD3 | P35462 | 6/20 | 0.67 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.67 |
| ▸ | HRH2 | P25021 | 6/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amperozide SCHEMBL1321270 | 0.99 | MEN1 (1.00) | CYP3A4CYP2D6MAPK1FAAHTSHR | |
| Amperozide SCHEMBL17360644 | 0.98 | CYP3A4 (0.95) | CYP3A4CYP2D6MAPK1FAAHTSHR | |
| SCHEMBL10556167 | 0.91 | CYP3A4 (0.83) | CYP3A4CYP2D6MAPK1FAAHTSHR | |
| Hydrochloric Acid SCHEMBL10510286 | 0.89 | MEN1 (0.83) | CYP3A4CYP2D6MAPK1FAAHTSHR | |
| Hydrochloric Acid SCHEMBL10510024 | 0.88 | KMT2A (0.81) | CYP3A4CYP2D6MAPK1FAAHTSHR | |
| Oxalic Acid SCHEMBL10506155 | 0.87 | MAPK1 (0.77) | CYP3A4CYP2D6MAPK1FAAHTSHR | |
| Hydrochloric Acid SCHEMBL10507007 | 0.86 | MEN1 (0.78) | CYP3A4CYP2D6MAPK1FAAHTSHR | |
| SCHEMBL10557106 | 0.85 | CYP3A4 (0.74) | CYP3A4CYP2D6MAPK1FAAHTSHR | |
| SCHEMBL10506450 | 0.85 | MAPK1 (0.74) | CYP3A4CYP2D6MAPK1FAAHTSHR | |
| SCHEMBL10509222 | 0.84 | MAPK1 (0.72) | CYP3A4CYP2D6MAPK1FAAHTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1069 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | TERRAN BIOSCIENCES INC (US) | 2025-02-13 | — | — | US | claimed |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-06-20 | — | — | US | claimed |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2024-05-23 | — | — | US | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | CONSEJO SUPERIOR INVESTIGACION (ES) | 2023-10-19 | — | — | US | claimed |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | TERRAN BIOSCIENCES, INC. (US) | 2023-08-15 | — | — | US | claimed |
| EP-0538422-B1 | NEW USE OF DIPHENYLBUTYLPIPERAZINECARBOXAMIDES IN THE TREATMENT OF SUBSTANCE DISORDERS | PHARMACIA & UPJOHN AB (SE) | 2001-02-07 | — | — | EP | claimed |
| WO-2000064441-A2 | COMPOUND FOR USE AS A MEDICAMENT FOR TREATMENT OF DISORDERS INVOLVING BRONCHOCONTRACTION | RESPIRATORIUS AB (SE) | 2000-11-02 | — | — | WO | claimed |
| EP-0517787-B1 | METHOD OF TREATING THERAPY-RESISTANT SCHIZOPHRENIA WITH AMPEROZIDE | PHARMACIA & UPJOHN AB (SE) | 1998-06-17 | — | — | EP | claimed |
| US-5618817-A | THERAPY OR PREVENTION OF WITHDRAWAL SYNDROME | KABI PHARMACIA AB (SE) | 1997-04-08 | — | — | US | claimed |
| US-5434156-A | Use of diphenylbutyl-piperazinecarboxamides in the treatment of substance disorders | PHARMACIA AB (SE) | 1995-07-18 | — | — | US | claimed |
| EP-0538422-A1 | NEW USE OF DIPHENYLBUTYLPIPERAZINECARBOXAMIDES IN THE TREATMENT OF SUBSTANCE DISORDERS | Pharmacia & Upjohn Aktiebolag (SE) | 1993-04-28 | — | — | EP | claimed |
| EP-0517787-A1 | METHOD OF TREATING THERAPY-RESISTANT SCHIZOPHRENIA WITH AMPEROZIDE | Pharmacia & Upjohn Aktiebolag (SE) | 1992-12-16 | — | — | EP | claimed |
| WO-1992016211-A1 | NEW USE OF DIPHENYLBUTYL-PIPERAZINECARBOXAMIDES IN THE TREATMENT OF SUBSTANCE DISORDERS | KABI PHARMACIA AB (SE) | 1992-10-01 | — | — | WO | claimed |
| WO-1991012805-A1 | METHOD OF TREATING THERAPY-RESISTANT SCHIZOPHRENIA WITH AMPEROZIDE | KABI PHARMACIA AB (SE) | 1991-09-05 | — | — | WO | claimed |
| US-5013735-A | Method of treating therapy-resistant schizophrenia with amperozide (N-ethyl-4-(4',4'-bis(p-fluorophenyl)butyl)-1-piperazine-carboxamide | PHARMACIA AB (SE) | 1991-05-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330063-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | CYP3A4 3603/4885CYP2D6 2224/4885MAPK1 2700/4885 |
| US-20250049748-A1 | ANALOGS OF 4-BROMO-2,5-DIMETHOXYPHENETHYLAMINE | PNMT, HNMT, COMT | CYP3A4 242/4885CYP2D6 84/4885MAPK1 3394/4885 |
| US-20240197681-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR3A | CYP3A4 2453/4885CYP2D6 1202/4885MAPK1 2335/4885 |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | HTR2A, HTR5A, HTR6 | CYP3A4 1995/4885CYP2D6 928/4885MAPK1 4129/4885 |
| US-20240165079-A1 | COMBINATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND/OR PSYCHIATRIC DISORDERS | HTR2A, HTR2C, HTR1A | CYP3A4 3683/4885CYP2D6 2262/4885MAPK1 3065/4885 |
| US-11723894-B2 | Combination product for the treatment of neurological and/or psychiatric disorders | HTR2A, HTR2C, HTR1A | CYP3A4 3683/4885CYP2D6 2262/4885MAPK1 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.